ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.27 Insider Own1.70% Shs Outstand145.62M Perf Week1.54%
Market Cap38.35M Forward P/E- EPS next Y-0.14 Insider Trans0.00% Shs Float145.21M Perf Month-6.04%
Income-34.80M PEG- EPS next Q-0.07 Inst Own13.70% Short Float1.69% Perf Quarter-38.21%
Sales2.70M P/S14.20 EPS this Y38.20% Inst Trans-30.86% Short Ratio2.11 Perf Half Y-65.08%
Book/sh-0.26 P/B- EPS next Y27.30% ROA-46.20% Target Price4.25 Perf Year-82.96%
Cash/sh0.24 P/C0.98 EPS next 5Y- ROE90.90% 52W Range0.16 - 1.67 Perf YTD-58.93%
Dividend- P/FCF- EPS past 5Y21.00% ROI162.80% 52W High-86.22% Beta0.60
Dividend %- Quick Ratio2.50 Sales past 5Y-30.50% Gross Margin-27.20% 52W Low43.81% ATR0.03
Employees43 Current Ratio2.50 Sales Q/Q-20.00% Oper. Margin- RSI (14)47.44 Volatility22.82% 15.71%
OptionableYes Debt/Eq- EPS Q/Q24.70% Profit Margin- Rel Volume2.71 Prev Close0.22
ShortableYes LT Debt/Eq- EarningsMay 16 BMO Payout- Avg Volume1.16M Price0.23
Recom2.50 SMA200.92% SMA50-12.34% SMA200-62.72% Volume3,150,494 Change3.23%
Jul-20-20Downgrade Credit Suisse Neutral → Underperform
Nov-11-19Downgrade Credit Suisse Outperform → Neutral $7 → $2
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Sep-15-16Reiterated ROTH Capital Buy $11.25 → $15
Aug-05-16Downgrade Stifel Buy → Hold
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
May-20-22 12:49PM  
May-19-22 11:56AM  
08:30AM  
May-16-22 08:45AM  
07:30AM  
May-12-22 05:35PM  
May-10-22 05:35PM  
08:30AM  
May-09-22 07:30PM  
Apr-27-22 08:00AM  
Apr-25-22 08:30AM  
Apr-21-22 08:30AM  
Mar-31-22 04:10PM  
Mar-29-22 01:08PM  
Mar-10-22 05:15PM  
04:01PM  
Mar-03-22 04:05PM  
Feb-01-22 08:30AM  
Jan-31-22 04:24AM  
Jan-27-22 01:38PM  
08:30AM  
Jan-12-22 08:30AM  
Jan-10-22 08:30AM  
Dec-23-21 08:05AM  
Dec-15-21 08:30AM  
Dec-01-21 07:12PM  
Nov-23-21 05:09PM  
Nov-15-21 06:45AM  
06:00AM  
Nov-10-21 08:30AM  
Nov-02-21 06:22AM  
Oct-28-21 03:06PM  
Oct-21-21 09:32PM  
Oct-04-21 07:30AM  
Sep-10-21 03:19PM  
Aug-30-21 05:10PM  
08:30AM  
Aug-26-21 08:30AM  
Aug-19-21 07:07AM  
Aug-16-21 05:25PM  
04:01PM  
Aug-12-21 04:01PM  
Aug-09-21 04:30PM  
01:30PM  
10:16AM  
10:00AM  
09:25AM  
08:30AM  
12:20AM  
Aug-08-21 01:00PM  
Aug-07-21 02:35PM  
Aug-06-21 09:33PM  
07:15PM  
02:30PM  
01:03PM  
01:00PM  
12:15PM  
10:00AM  
Aug-05-21 11:25AM  
Aug-04-21 08:00PM  
12:00PM  
11:20AM  
11:05AM  
10:00AM  
01:17AM  
Aug-03-21 10:45PM  
12:00PM  
11:18AM  
Aug-02-21 10:24PM  
03:01PM  
01:05PM  
12:30PM  
11:00AM  
10:33AM  
Jul-31-21 11:00AM  
Jul-30-21 07:23PM  
07:10PM  
Jul-29-21 12:45PM  
12:45PM  
10:00AM  
Jul-28-21 08:00PM  
07:18PM  
11:00AM  
Jul-27-21 11:15AM  
11:00AM  
Jul-26-21 10:03PM  
03:12PM  
02:00PM  
01:00PM  
Jul-25-21 11:00AM  
Jul-23-21 08:49PM  
01:30PM  
Jul-22-21 11:00AM  
Jul-21-21 09:30PM  
08:00PM  
01:05PM  
11:05AM  
Jul-20-21 07:15PM  
01:40PM  
01:00PM  
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.